Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H8EO
|
|||
| Former ID |
DNC010136
|
|||
| Drug Name |
3,3-diethyl-1-phenylazetidine-2,4-dione
|
|||
| Synonyms |
3,3-diethyl-1-phenylazetidine-2,4-dione; CHEMBL272413; 2,4-Azetidinedione, 3,3-diethyl-1-phenyl-; 15745-94-5; 3,3-Diethyl-1-phenylazetidin-2,4-dione; AC1L3FYP; DTXSID30166264; KDXSTYUPRNLDGW-UHFFFAOYSA-N; BDBM50235613; 1-Phenyl-3,3-diethylazetidine-2,4-dione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H15NO2
|
|||
| Canonical SMILES |
CCC1(C(=O)N(C1=O)C2=CC=CC=C2)CC
|
|||
| InChI |
1S/C13H15NO2/c1-3-13(4-2)11(15)14(12(13)16)10-8-6-5-7-9-10/h5-9H,3-4H2,1-2H3
|
|||
| InChIKey |
KDXSTYUPRNLDGW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 15745-94-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neutrophil elastase (NE) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| Systemic lupus erythematosus | ||||
| Pathway Interaction Database | Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | |||
| C-MYB transcription factor network | ||||
| Reactome | Collagen degradation | |||
| Degradation of the extracellular matrix | ||||
| Activation of Matrix Metalloproteinases | ||||
| WikiPathways | Hair Follicle Development: Cytodifferentiation (Part 3 of 3) | |||
| Human Complement System | ||||
| Degradation of collagen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 4-Oxo-beta-lactams (azetidine-2,4-diones) are potent and selective inhibitors of human leukocyte elastase. J Med Chem. 2010 Jan 14;53(1):241-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.